Search hospitals > Michigan > Flint

Genesee Hematology Oncology PC

Claim this profile
Flint, Michigan 48503
Global Leader in Skin Cancer
Global Leader in Lung Cancer
Conducts research for Breast Cancer
Conducts research for Cancer
Conducts research for Non-Small Cell Lung Cancer
178 reported clinical trials
7 medical researchers
Photo of Genesee Hematology Oncology PC in FlintPhoto of Genesee Hematology Oncology PC in FlintPhoto of Genesee Hematology Oncology PC in Flint

Summary

Genesee Hematology Oncology PC is a medical facility located in Flint, Michigan. This center is recognized for care of Skin Cancer, Lung Cancer, Breast Cancer, Cancer, Non-Small Cell Lung Cancer and other specialties. Genesee Hematology Oncology PC is involved with conducting 178 clinical trials across 351 conditions. There are 7 research doctors associated with this hospital, such as Tareq Al Baghdadi, Christopher M. Reynolds, MD, Philip J. Stella, and Elie G. Dib.

Area of expertise

1Skin Cancer
Global Leader
Genesee Hematology Oncology PC has run 81 trials for Skin Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage II
2Lung Cancer
Global Leader
Genesee Hematology Oncology PC has run 35 trials for Lung Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage II

Top PIs

Clinical Trials running at Genesee Hematology Oncology PC

Breast Cancer
Lung Cancer
Skin Cancer
Non-Small Cell Lung Cancer
Breast cancer
Ovarian Cancer
Cancer
Bladder Cancer
Stomach Cancer
Multiple Myeloma
Image of trial facility.

Chemotherapy + Hormone Therapy

for Breast Cancer

This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
Image of trial facility.

Low Dose Tamoxifen

for Breast Cancer

This phase III trial compares the effect of low dose tamoxifen to usual hormonal therapy, including aromatase inhibitors, in treating post-menopausal women with hormone positive, HER2 negative early stage breast cancer. Tamoxifen is in a class of medications known as antiestrogens. It blocks the activity of estrogen (a female hormone) in the breast. This may stop the growth of some breast tumors that need estrogen to grow. Aromatase inhibitors, such as anastrozole, letrozole, and exemestane, prevent the formation of estradiol, a female hormone, by interfering with an aromatase enzyme. Aromatase inhibitors are used as a type of hormone therapy to treat postmenopausal women with hormone-dependent breast cancer. Giving low dose tamoxifen may be more effective compared to usual hormone therapy in treating post-menopausal women with hormone-positive, HER2 negative early stage breast cancer.
Recruiting2 awards Phase 38 criteria
Image of trial facility.

Shorter Chemo-Immunotherapy Without Anthracyclines

for Breast Cancer

This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Recruiting2 awards Phase 347 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Genesee Hematology Oncology PC?
Genesee Hematology Oncology PC is a medical facility located in Flint, Michigan. This center is recognized for care of Skin Cancer, Lung Cancer, Breast Cancer, Cancer, Non-Small Cell Lung Cancer and other specialties. Genesee Hematology Oncology PC is involved with conducting 178 clinical trials across 351 conditions. There are 7 research doctors associated with this hospital, such as Tareq Al Baghdadi, Christopher M. Reynolds, MD, Philip J. Stella, and Elie G. Dib.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security